Mercaptopurine Silver

Mercaptopurine, the active ingredient in Mercaptopurine Silver, is a purine analog antimetabolite presented as an oral formulation for oral use. It is employed in the treatment of certain leukemias and inflammatory bowel diseases, targeting rapidly dividing cells and modulating immune response.

GNH USA supplies Mercaptopurine Silver as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Mercaptopurine is used in conditions where inhibition of purine synthesis is therapeutic, particularly in hematologic malignancies and inflammatory bowel disorders. - Acute lymphoblastic leukemia: helps achieve remission by suppressing malignant lymphoblast proliferation. - Crohn's disease: reduces intestinal inflammation and maintains clinical remission. - Ulcerative colitis: controls mucosal inflammation and promotes disease remission.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Vomiting: occasional episodes after dosing. - Diarrhea: loose stools that may affect hydration. - Rash: skin redness or itching. - Headache: transient cranial discomfort. - Mild elevation of liver enzymes: detectable on routine labs.

Serious or Rare Side Effects: - Severe bone marrow suppression: profound leukopenia or pancytopenia. - Hepatotoxicity: significant liver injury with jaundice. - Pancreatitis: acute inflammation of the pancreas. - Life‑threatening infections: opportunistic infections due to immunosuppression. - Hypersensitivity reactions: including Stevens‑Johnson syndrome. - Secondary malignancies: rare development of other cancers.

Careful monitoring and patient education are essential when using mercaptopurine. - Blood count monitoring: perform regular CBC to detect myelosuppression. - Liver function testing: assess transaminases before and during therapy. - Renal function assessment: adjust use in patients with impaired clearance. - Pregnancy considerations: avoid unless benefits outweigh potential fetal risks. - Concomitant drug review: evaluate for interactions that may increase toxicity. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct light.

Mercaptopurine may interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Allopurinol: increases mercaptopurine toxicity; dose reduction required. - Azathioprine: additive myelosuppression risk. - Warfarin: potentiates anticoagulant effect, increasing bleeding risk. - Xanthine oxidase inhibitors: elevate plasma levels, heightening adverse effects. - TPMT deficiency (genetic): leads to severe bone marrow suppression.

Moderate Interactions (Monitor Closely): - NSAIDs: may worsen renal impairment. - Sulfonamides: potential additive bone marrow suppression. - Oral contraceptives: possible reduction in hormonal efficacy. - Methotrexate: combined immunosuppression may increase infection risk. - Ribavirin: may enhance hematologic toxicity.